Skip to main content
Log in

Increased serum APRIL differentially correlates with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Cytokines play an important role in the pathogenesis of systemic lupus erythematosus (SLE). Among the cytokines that regulate B cell homeostasis is a proliferation-inducing ligand (APRIL). This study aimed to determine whether serum levels of APRIL are raised in patients with SLE and correlate with disease activity or proinflammatory cytokines production, or both. Serum APRIL, interleukin-17 (IL-17), IL-4 and interferon gamma (IFN-γ) levels were measured in forty patients with SLE and 30 healthy controls. Disease activity was assessed by SLE disease activity index (SLEDAI), and results were correlated with serum APRIL levels. Serum APRIL levels were significantly higher in patients with SLE than in healthy controls. Positive correlation was found between serum APRIL levels and total SLEDAI score and anti-dsDNA antibody titers. Moreover, serum APRIL levels was significantly higher in patients with arthritis, mucocutaneous manifestations and proteinuria. APRIL is increased in patients with active SLE accompanying the increase of IL-17 and IFN-γ. Significant positive correlations between serum levels of APRIL and IL-17 and IFN-γ and a negative correlation between serum levels of APRIL and IL-4 were found. The results suggest that APRIL may be an important marker of disease activity in patients with SLE. We provide the analyses of APRIL levels in patients with SLE, suggesting new tools for the diagnosis, prognosis and possible therapeutic management of SLE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Adhya Z, Borozdenkova S, Karim MY (2011) The role of cytokines as biomarkers in systemic lupus erythematosus and lupus nephritis. Nephrol Dial Transplant 26:3273–3280

    Article  CAS  PubMed  Google Scholar 

  2. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG (1990) Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 33:634–643

    Article  PubMed  Google Scholar 

  3. Kavanaugh AF, Solomon DH (2002) Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum 47:546–555

    Article  CAS  PubMed  Google Scholar 

  4. Chun HY, Chung JW, Kim HA, Yun JM, Jeon JY, Ye YM, Kim SH, Park HS, Suh CH (2007) Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 27:461–466

    Article  CAS  PubMed  Google Scholar 

  5. Ohl K, Tenbrock K (2011) Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol 2011:432595

  6. Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE, Sordat B, Rimoldi D, Tschopp J (1998) APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 188:1185–1190

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189:1747–1756

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, Hession C, Schneider P, Sizing ID, Mullen C, Strauch K, Zafari M, Benjamin CD, Tschopp J, Browning JL, Ambrose C (2001) BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293:2108–2111

    Article  CAS  PubMed  Google Scholar 

  9. Hendriks J, Planelles L, de Jong-Odding J, Hardenberg G, Pals ST, Hahne M, Spaargaren M, Medema JP (2005) Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ 12:637–648

    Article  CAS  PubMed  Google Scholar 

  10. Ingold K, Zumsteg A, Tardivel A, Huard B, Steiner QG, Cachero TG, Qiang F, Gorelik L, Kalled SL, Acha-Orbea H, Rennert PD, Tschopp J, Schneider P (2005) Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 201:1375–1383

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Krivosikova M, Dallos T, Maslinski W, Buc M (2009) B cell activating factor, its role in autoimmunity, and targeting in autoimmune diseases. Bratisl Lek Listy 110:137–145

    CAS  PubMed  Google Scholar 

  12. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W, Clegg CH (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404:995–999

    Article  CAS  PubMed  Google Scholar 

  13. Koyama T, Tsukamoto H, Masumoto K, Himeji D, Hayashi K, Harada M, Horiuchi T (2003) A novel polymorphism of the human APRIL gene is associated with systemic lupus erythematosus. Rheumatology 42:980–985

    Article  CAS  PubMed  Google Scholar 

  14. Seyler TM, Park YW, Takemura S, Bram RJ, Kurtin PJ, Goronzy JJ, Weyand CM (2005) BLyS and APRIL in rheumatoid arthritis. J Clin Invest 115:3083–3092

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K (2005) Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren’s syndrome. J Clin Immunol 25:189–201

    Article  CAS  PubMed  Google Scholar 

  16. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, Roschke V, Wu Y, Baker KP, Hilbert DM (2003) B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 48:3475–3486

    Article  PubMed  Google Scholar 

  17. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725

    Article  CAS  PubMed  Google Scholar 

  18. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640

    Article  CAS  PubMed  Google Scholar 

  19. Cook RJ, Gladman DD, Pericak D, Urowitz MB (2000) Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity. J Rheumatol 27:1892–1895

    CAS  PubMed  Google Scholar 

  20. Nalbandian A, Crispin JC, Tsokos GC (2009) Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 157:209–215

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Elewa E, Zakaria O, Mohamed E, Boghdadi G (2014) The role of interleukins 4, 17 and interferon gamma as biomarkers in patients with Systemic Lupus Erythematosus and their correlation with disease activity. Egypt Rheumatol 36:21–27

    Article  Google Scholar 

  22. Hegazy M, Darwish H, Darweesh H, El-Shehaby A, Emad Y (2010) Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices. Clin Immunol 135:118–124

    Article  CAS  PubMed  Google Scholar 

  23. Morel J, Roubille C, Planelles L, Rocha C, Fernandez L, Lukas C, Hahne M, Combe B (2009) Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus. Ann Rheum Dis 68:997–1002

    Article  CAS  PubMed  Google Scholar 

  24. Koyama T, Tsukamoto H, Miyagi Y, Himeji D, Otsuka J, Miyagawa H, Harada M, Horiuchi T (2005) Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 64:1065–1067

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A (2000) Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 10:785–788

    Article  CAS  PubMed  Google Scholar 

  26. Stein JV, Lopez-Fraga M, Elustondo FA, Carvalho-Pinto CE, Rodriguez D, Gomez-Caro R, De Jong J, Martinez AC, Medema JP, Hahne M (2002) APRIL modulates B and T cell immunity. J Clin Invest 109:1587–1598

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, Cerutti A (2002) DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 3:822–829

    Article  CAS  PubMed  Google Scholar 

  28. Chu VT, Enghard P, Schurer S, Steinhauser G, Rudolph B, Riemekasten G, Berek C (2009) Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum 60:2083–2093

    Article  CAS  PubMed  Google Scholar 

  29. Stohl W (2010) Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes). Arthritis Res Ther 12:111

    Article  PubMed Central  PubMed  Google Scholar 

  30. Treamtrakanpon W, Tantivitayakul P, Benjachat T, Somparn P, Kittikowit W, Eiam-Ong S, Leelahavanichkul A, Hirankarn N, Avihingsanon Y (2012) APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis. Arthritis Res Ther 14:R252

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, Migone TS, Hilbert DM, Stohl W (2003) Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 48:982–992

    Article  CAS  PubMed  Google Scholar 

  32. George-Chandy A, Trysberg E, Eriksson K (2008) Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther 10:R97

    Article  PubMed Central  PubMed  Google Scholar 

  33. Xiao Y, Motomura S, Podack ER (2008) APRIL (TNFSF13) regulates collagen-induced arthritis, IL-17 production and Th2 response. Eur J Immunol 38:3450–3458

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Dr. Wael Galal Abdalazem for his help in the statistical analysis.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ghada Boghdadi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boghdadi, G., Elewa, E.A. Increased serum APRIL differentially correlates with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients. Rheumatol Int 34, 1217–1223 (2014). https://doi.org/10.1007/s00296-014-3020-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-014-3020-4

Keywords

Navigation